Type I interferon signaling promotes mucosal inflammation in murine models of colitis

This study demonstrates that Type I interferon signaling drives mucosal inflammation in inflammatory bowel disease by upregulating myeloid cell responses, as evidenced by elevated signatures in human patients and increased disease susceptibility in mice, while postnatal inhibition of this pathway offers protection against colitis.

The Gist

The Big Picture: A Misunderstood Bodyguard

Imagine your body's immune system is like a highly trained security team for a city (your gut). Their job is to spot invaders (like viruses) and call for backup.

One specific type of backup call is the Type I Interferon (IFN-I) signal. Think of this signal as a "Code Red" siren. Usually, this siren is great because it wakes up the security guards to fight off a virus.

The Problem: In people with Inflammatory Bowel Disease (IBD), like Ulcerative Colitis, this "Code Red" siren seems to be stuck in the "ON" position, even when there is no virus. Instead of protecting the city, the constant screaming is causing chaos, damaging the buildings (the gut lining), and making the inflammation worse.

This paper argues that turning down this siren could actually help heal the gut.

---

The Investigation: Finding the Noise

1. Listening to the Patients (Human Data)
The researchers looked at tissue samples from people with active Ulcerative Colitis. They used a high-tech "microphone" (RNA sequencing) to listen to what genes were shouting.

• What they heard: The "IFN-I siren" genes were screaming louder than in healthy people or people whose disease was quiet.
• Who was shouting: They zoomed in to see which cells were making the noise. It turned out to be the myeloid cells (a type of immune cell, like the heavy-duty riot police) that had moved into the gut lining. These cells were also wearing more "ears" (receptors) to hear the siren, making them extra sensitive.

2. Testing in the Lab (Mouse Models)
To prove this wasn't just a coincidence, they tested it in mice.

• The "Super-Listener" Mice: They created mice that had a broken switch, making their "ears" (IFNAR1 receptors) stay open all the time. These mice didn't get sick on their own, but their immune systems were on high alert. When they were exposed to a mild gut irritant (DSS), they got much sicker than normal mice. Their guts were more inflamed and shorter.
• The "Silenced" Mice: Then, they did the opposite. They used a special "mute button" (an antibody or a genetic switch) to turn off the IFN-I signal in adult mice after they were already sick.
• The Result: The mice with the signal turned off got much better. Their inflammation went down, and their guts healed faster.

The Twist: Why Previous Studies Were Confused

You might wonder, "Wait, I thought Interferons were good?"
The paper explains that previous studies were confusing because they looked at mice that were born without these receptors (a "germline knockout").

• The Analogy: Imagine a city that never had a police force because it was built that way. The city might develop strange, weird ways of handling crime because it never learned how to use a police force.
• The Fix: This study used "adult" mice where they turned the signal off after the city was already built. This showed that in a mature system, the signal is actually causing the problem, not preventing it.

The Takeaway: A New Way to Treat IBD

Currently, many IBD treatments try to calm down the general immune system. This paper suggests a more targeted approach:

1. The "Siren" is the culprit: In many IBD patients, the Type I Interferon pathway is driving the fire, not fighting it.
2. New Tools: There are already drugs (like JAK inhibitors) and antibodies (like those used for Lupus) that can block this specific signal.
3. The Future: Doctors might be able to test a patient's gut tissue. If they see a lot of "IFN-I noise," they could use these specific blockers to turn the siren off, potentially helping patients who aren't responding to current treatments.

Summary in One Sentence

This study discovered that in Inflammatory Bowel Disease, a specific immune alarm system (Type I Interferon) is stuck on "high alert," causing more damage than good, and turning that alarm off in mice helped heal their guts, suggesting a promising new treatment for humans.

Technical Summary

1. Problem Statement

The role of Type I Interferons (IFN-I) in Inflammatory Bowel Disease (IBD) has been controversial and poorly defined.

• Conflicting Evidence: While IFN-I is known for antiviral and immunomodulatory properties (often anti-inflammatory, e.g., in Multiple Sclerosis), clinical trials of IFN-β in IBD showed no efficacy, and IFN-I therapy has occasionally triggered colitis in patients.
• Genetic Context: Conversely, genetic disorders with early-onset IBD (e.g., XLPDR) are linked to hyperactive IFN-I signaling.
• Pre-clinical Discrepancies: Mouse models have yielded contradictory results. Some studies suggest IFN-I is protective, while others suggest it is detrimental. Global knockout models ($Ifnar1^{-/-}$) show variable phenotypes, potentially confounded by developmental defects caused by lifelong IFN-I deprivation.
• Knowledge Gap: There is a lack of consensus on whether IFN-I drives pathogenesis in active IBD and whether acute inhibition of this pathway offers therapeutic potential.

2. Methodology

The authors employed a multi-faceted approach combining human transcriptomics, single-cell analysis, and diverse murine genetic/pharmacologic models.

• Human Cohort Analysis:
  • Bulk RNA-seq: Performed on colonic biopsies from non-IBD controls, inactive UC, and active UC patients.
  • Single-Cell RNA-seq (scRNA-seq): Re-analyzed public datasets (GSE182270, GSE214695) to deconvolute cell-type-specific expression of IFN-I signature genes.
  • Validation: Used qRT-PCR and immunofluorescence (IF) for ISG15 and STAT1 protein expression in human biopsies.
• Murine Models:
  • Gain-of-Function (GOF): Used Ifnar1^S535A (SA) mice. This mutation prevents phosphorylation-dependent ubiquitination of the IFNAR1 receptor, leading to receptor stabilization and heightened basal IFN-I signaling.
  • Loss-of-Function (LOF) - Genetic: Used a tamoxifen-inducible, post-natal global deletion of Ifnar1 (Ifnar1^fl/fl; Ubc-CreERT2) to avoid developmental confounders.
  • Loss-of-Function (LOF) - Pharmacologic: Administered a blocking anti-IFNAR1 antibody to Wild-Type (WT) mice during colitis induction.
  • Colitis Induction:
    • DSS-induced colitis: Standard chemical induction in WT, SA, and conditional KO mice.
    • Piroxicam-accelerated enterocolitis: Used in Il10^-/- mice crossed with SA mice to model spontaneous, severe IBD.
• Assays: Mass cytometry (CyTOF) for immune profiling, flow cytometry for receptor expression, qRT-PCR for cytokine/ISG quantification, and histological scoring (Disease Activity Index, colon length).

3. Key Contributions

• Resolution of Cell-Type Specificity: The study definitively identifies CD14+ myeloid cells as the primary cellular source of upregulated IFN-I signature genes in active IBD, rather than epithelial cells.
• Mechanistic Clarification: It distinguishes between the effects of developmental loss of IFN-I (which may cause epithelial restitution defects) and acute pathogenic signaling. The study argues that previous conflicting data in global knockouts may be due to developmental compensation or defects, whereas acute inhibition reveals the true pathogenic role.
• Therapeutic Validation: It provides pre-clinical proof-of-concept that acute inhibition of IFNAR1 (via genetic deletion or antibody blockade) protects against experimental colitis, supporting the repurposing of anti-IFNAR1 therapies (currently used for SLE) for IBD.

4. Key Results

A. Human IBD Data

• Transcriptomic Signature: Active UC biopsies showed significant upregulation of IFN-I and IFN-II signature genes compared to inactive UC or controls.
• Cellular Localization: scRNA-seq analysis revealed that the upregulation of IFN-I signature genes (e.g., ISG15, STAT1, IFITM2) was most prominent in CD14+ myeloid cells.
• Receptor Expression: CD14+ myeloid cells in active UC exhibited increased expression of IFN-I receptors (IFNAR1/IFNAR2) and IFN-II receptors, but not IFN-III receptors. Flow cytometry confirmed that in inflamed mouse colon, the majority of IFNAR1+ cells are immune cells (CD45+), and they express higher receptor levels than epithelial cells.

B. Murine Gain-of-Function (SA Mice)

• Basal State: SA mice exhibited elevated surface IFNAR1 and higher basal expression of IFN-I signature genes in the colon and spleen.
• Immune Homeostasis: Despite no spontaneous colitis, SA mice showed altered immune homeostasis: increased proportion of immune cells in the colon, reduced epithelial proportion, and an activated pro-inflammatory phenotype (elevated CD86, LY6C).
• Susceptibility: SA mice were significantly more susceptible to both DSS-induced colitis and piroxicam-accelerated enterocolitis (in Il10^-/- background), exhibiting severe weight loss, higher disease activity scores, colon shortening, and elevated inflammatory cytokines.

C. Murine Loss-of-Function (Inhibition)

• Post-natal Deletion: Tamoxifen-induced deletion of Ifnar1 in adult mice conferred strong protection against DSS-induced colitis (reduced disease activity, preserved colon length, lower cytokine/ISG expression).
• Antibody Blockade: Treatment with an anti-IFNAR1 blocking antibody during DSS exposure mimicked the genetic deletion phenotype, significantly ameliorating colitis severity.
• Weight Note: Interestingly, while disease activity improved, body weight loss was not significantly different between treated and control groups in some models, suggesting IFN-I signaling drives local inflammation more than systemic wasting in this context.

5. Significance

• Paradigm Shift: The study challenges the view that IFN-I is merely a bystander or protective factor in IBD, establishing it as a pathogenic driver of mucosal inflammation.
• Clinical Implications:
  • Biomarker: The IFN-I signature (ISG expression) may serve as a marker for disease activity and potentially predict resistance to anti-TNF therapy.
  • Therapeutic Target: The findings provide a strong rationale for clinical trials of IFNAR1 blockade (e.g., anti-IFNAR1 antibodies) or JAK1/TYK2 inhibitors (which block downstream IFN signaling) specifically in IBD patients with high ISG signatures.
• Methodological Insight: The study highlights the importance of distinguishing between developmental and acute effects of cytokine signaling, suggesting that therapeutic strategies should target the acute inflammatory phase rather than relying on global genetic models that alter development.

In conclusion, this paper provides robust evidence that dysregulated Type I Interferon signaling, particularly within myeloid cells, exacerbates intestinal inflammation, offering a clear mechanistic pathway for novel therapeutic interventions in IBD.